Sanofi-Aventis loses Lovenox patent case

Share this article:
Sanofi-Aventis said today it lost a patent infringement case against two generic drug makers involving its top-selling product, the blockbuster bloodthinner Lovenox. Amphastar Pharmaceuticals and Teva Pharmaceutical Industries have been planning to launch generic versions of Lovenox, even though the drug’s patent doesn’t expire until 2012. Yesterday’s trial results may assist those generics companies in achieving their goals. The trial, which took place in the US District Court for the Central District of California, was to determine whether Sanofi-Aventis engaged in inequitable conduct when it initially filed the Lovenox patent. Proving inequitable conduct, which may include submission of incomplete documents when applying for a patent, could invalidate the entire patent. Despite their court victory, Amphastar and Teva face difficulties in getting their versions of Lovenox approved by the FDA. The drug, derived from pig intestines, requires a complex manufacturing process that is difficult to replicate. Lovenox is also under threat by generic drugmaker Momenta Pharmaceuticals, which has reportedly teamed with Novartis’ generics unit Sandoz. Sanofi-Aventis said in a statement that it is “currently evaluating its options for further legal recourse” and will continue to “vigorously defend its intellectual property rights.” In addition to Lovenox, Sanofi-Aventis is also defending its second best selling product, the jointly-marketed antiplatelet agent Plavix, in a US court. Sanofi-Aventis markets Plavix with Bristol-Myers Squibb. Worldwide sales of Lovenox for 2005 were $2.5 billion. Global sales of Plavix were $3.8 billion in 2005.
Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.